Health In Tech Inc (HIT) Stock Analysis
Verdict: AVOID
Rapid revenue growth is overshadowed by deteriorating technicals and persistent negative margins in a high-beta microcap environment.
Investment score: 38/100
Analysis as of
Is Health In Tech Inc stock worth reviewing? The TradeMates thesis
Health In Tech shows impressive top-line scale-up but fails the 'quality' test due to lack of sustainable FCF and heavy selling pressure.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 50/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 55/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Health In Tech Inc opportunities and risks
What speaks for HIT
- Aggressive Revenue Scaling
What speaks against HIT
- Profitability Gap
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| HIT | n/a | 1.7x | n/a | 58.9% | -2.4% | -2.1% |
| LIFE | n/a | 2.3x | n/a | 97.1% | -22.1% | 3.3% |
| TWFG | 36.4x | 1.1x | 2.1x | 29.2% | 3.3% | 16.9% |
| ABX | 22.1x | 3.4x | 10.2x | 70.8% | 15.6% | 14.7% |
| SLQT | 1.7x | 0.1x | 3.6x | 59.3% | 5.6% | -9.0% |
| Peer median | 11.9x | 1.7x | 2.8x | 65.1% | 4.4% | 9.0% |
Frequently asked questions about Health In Tech Inc (HIT)
Is HIT stock a good investment?
The TradeMates model rates Health In Tech Inc as AVOID with an investment score of 38/100. Health In Tech shows impressive top-line scale-up but fails the 'quality' test due to lack of sustainable FCF and heavy selling pressure. This is algorithmic model output, not personal investment advice.
Is HIT stock a buy?
The TradeMates model verdict for HIT is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.